JaLCDOI 10.18926/AMO/48266
FullText URL 66_2_163.pdf.pdf
Author Utsumi, Hiroya| Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group|
Abstract Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17オ and 34オ (hazard ratio, 0.57;95オ confidence interval, 0.18‒1.81;p=0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.
Keywords cabergoline levodopa Parkinsonʼs disease motor complications
Amo Type Original Article
Published Date 2012-04
Publication Title Acta Medica Okayama
Volume volume66
Issue issue2
Publisher Okayama University Medical School
Start Page 163
End Page 170
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2012 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22525474
Web of Science KeyUT 000303175300009